Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
506.00    1.00 (0.20%)
Bid:
504.50
Ask:
508.00
Spread: 3.50 (0.694%)
Market Cap: £2.24b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Director Declaration

10 Nov 2025 14:40

RNS Number : 9211G
Tate & Lyle PLC
10 November 2025
 

10 November 2025

 

Tate & Lyle PLC

 

 

DIRECTOR DECLARATION

 

Notification regarding external directorships

 

In accordance with Listing Rule 6.4.9(2), Tate & Lyle PLC announces that Sarah Kuijlaars, Chief Financial Officer, has notified the Company that she has been appointed as a non-executive director of JD Sports Fashion Plc (with effect from 10 November 2025).

 

On appointment, Sarah will become a member of the Audit and Risk Committee and the Nomination Committee. Sarah will be appointed as Chair of the Audit and Risk Committee with effect from 1 June 2026.

 

 

END

 

For more information contact:

 

For Tate & Lyle PLC

 

Investors and analysts

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Media

Nick Hasell, FTI Consulting

Tel: Mobile: +44 (0) 7825 523 383

Tel: Office: +44 (0) 203 727 1340

Email: tate@fticonsulting.com

 

About Tate & Lyle PLC:

 

Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day.

 

Through our leading expertise in sweetening, mouthfeel and fortification, we develop ingredients and solutions which reduce sugar, calories and fat, add fibre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

 

Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 38 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2025, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2024, revenue for the enlarged Tate & Lyle Group would have been £2.12 billion. For more information, please visit www.tateandlyle.com or follow Tate & Lyle on LinkedInX (Twitter)Facebook or YouTube.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNZBLFFEFLXFBK
Date   Source Headline
29th Apr 20253:30 pmRNSHolding(s) in Company
28th Apr 20255:15 pmRNSHolding(s) in Company
24th Apr 202512:00 pmRNSHolding(s) in Company
15th Apr 20257:00 amRNSIntegration update and pre-close statement
27th Mar 20257:00 amRNSDirectorate Change
14th Mar 202510:05 amRNSDirectorate declaration
11th Mar 20253:00 pmRNSHolding(s) in Company
5th Mar 202511:30 amRNSDirector/PDMR Shareholding
28th Feb 20254:30 pmRNSHolding(s) in Company
28th Feb 202510:15 amRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSAdditional Listing
20th Feb 20251:42 pmRNSDirector/PDMR Shareholding
13th Feb 20257:00 amRNSTrading Statement
4th Feb 20257:05 amRNSDirector Declaration
3rd Feb 20253:30 pmRNSTotal Voting Rights
23rd Jan 20255:30 pmRNSIssue of Debt
9th Jan 20255:54 pmRNSCompletion of Share Buyback Programme
9th Jan 20255:45 pmRNSTransaction in Own Shares
8th Jan 20255:17 pmRNSTransaction in Own Shares
8th Jan 20252:02 pmRNSDirector/PDMR Shareholding
7th Jan 20255:31 pmRNSTransaction in Own Shares
6th Jan 20256:10 pmRNSTransaction in Own Shares
6th Jan 20252:00 pmRNSDirectorate Change
3rd Jan 20255:28 pmRNSTransaction in Own Shares
2nd Jan 20255:20 pmRNSTransaction in Own Shares
2nd Jan 20252:10 pmRNSBlock listing Interim Review
2nd Jan 20252:00 pmRNSTotal Voting Rights
30th Dec 20245:36 pmRNSTransaction in Own Shares
27th Dec 20245:15 pmRNSTransaction in Own Shares
23rd Dec 20245:26 pmRNSTransaction in Own Shares
20th Dec 20245:31 pmRNSTransaction in Own Shares
19th Dec 20245:24 pmRNSTransaction in Own Shares
18th Dec 20245:37 pmRNSTransaction in Own Shares
17th Dec 20245:20 pmRNSTransaction in Own Shares
16th Dec 20245:37 pmRNSTransaction in Own Shares
13th Dec 20245:25 pmRNSTransaction in Own Shares
12th Dec 20245:34 pmRNSTransaction in Own Shares
12th Dec 20245:30 pmRNSDirector/PDMR Shareholding
11th Dec 20245:28 pmRNSTransaction in Own Shares
10th Dec 20245:32 pmRNSTransaction in Own Shares
9th Dec 20245:25 pmRNSTransaction in Own Shares
6th Dec 20245:33 pmRNSTransaction in Own Shares
5th Dec 20245:38 pmRNSTransaction in Own Shares
5th Dec 20242:30 pmRNSHolding(s) in Company
5th Dec 20242:00 pmRNSDirector/PDMR Shareholding
4th Dec 20245:32 pmRNSTransaction in Own Shares
4th Dec 20244:00 pmRNSHolding(s) in Company
3rd Dec 20245:21 pmRNSTransaction in Own Shares
3rd Dec 20243:00 pmRNSHolding(s) in Company
2nd Dec 20245:31 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.